Article Text

Download PDFPDF

363 Identification of dark antigen® reactive T cell receptors from tumor-infiltrating lymphocytes
  1. Thomas M Hulen1,
  2. Michael D Crowther2,
  3. Shawez Khan1,
  4. Aimilia Schina2,
  5. Duncan Howie3,
  6. Özcan Met2 and
  7. Inge Svane2
  1. 1Center for Cancer Immune Therapy, Herlev, Denmark
  2. 2National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
  3. 3Enara Bio Ltd, Oxford, UK
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.

Abstract

Background Adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TILs) is an effective therapy for advanced melanoma, with response rates between 30–50%.1 2 However, the majority of patients do not respond, and immunological targets of TIL TCRs remain elusive.3 Dark Antigens are cancer specific targets discovered in regions of the genome historically considered noncoding. Due to their intratumoral homogeneity and shared expression between individuals, they make attractive immunotherapeutic targets. Using the EDAPT® (Enara Dark Antigen Platform Technology) platform, Enara Bio® has identified numerous, melanoma-specific translated peptides, derived from Dark Antigens, and presented on Class I MHC by primary tumors.4 5 We sought to demonstrate that patient-derived melanoma cell lines express Dark Antigen transcripts, identify Dark Antigen-reactivity in TILs from these patients, and identify and validate the reactivity of anti-Dark Antigen TCRs.

Methods mRNA sequencing data from patient-derived melanoma cell lines was evaluated for Dark Antigen transcript expression. TILs derived from these patients were stimulated with Dark Antigen peptide and screened in ELISPOT for IFNγ production. Dark Antigen reactive TILs from one patient were isolated and TCR sequences of reactive cells were obtained by integration of gene expression and VDJ single cell sequencing data (10X Genomics). Through lentiviral transduction selected TCRs were expressed in healthy donor T cells (TCR-Ts) and functionally evaluated using ELISPOT, intracellular cytokine staining (ICS), and chromium-51 (Cr51) killing assay.

Results Dark Antigen transcripts EVA001, EVA002, or EVA003 are expressed in 70% of patient-derived melanoma lines investigated from our biobank. Peptide #1, derived from EVA003, stimulated significant IFNγ release from TIL isolated from a single patient. Three Peptide #1-reactive candidate TCRs were identified by single cell sequencing. One TCR demonstrated EVA003-Peptide #1 specific functional activity as a derivative TCR-T through production of cytokines IFNγ and TNFα, upregulation of activation markers CD137 and CD107a and cytolysis of HLA-A3-positive target cells pulsed with Dark Antigen Peptide #1.

Conclusions Using clinical material from our melanoma biobank we have confirmed the broad expression of Dark Antigen transcripts across patients, identified Dark Antigen reactive TILs, and validated the discovery of a specific Dark Antigen reactive TCR. Ongoing investigations will utilize clinical tumor samples as target cells to evaluate TCR-T specific reactivity against in situ Dark Antigen expression. This study highlights the potential of Dark Antigens to address the need for novel cancer-specific targets for solid tumors.

References

  1. Haanen JB, et al. Treatment with tumor-infiltrating lymphocytes (TIL) versus ipilimumab for advanced melanoma: Results from a multicenter, randomized phase III trial. Annals of Oncology 2022;33(suppl_7):S808-S869. 10.1016/annonc/annonc1089

  2. Chesney J, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144–01 study. J Immunother Cancer. 2022 Dec;10(12):e005755

  3. Hulen TM, et al. ACT Up TIL Now: The Evolution of Tumor-Infiltrating Lymphocytes in Adoptive Cell Therapy for the Treatment of Solid Tumors. Immuno. 2021;1(3):194–211.

  4. Abbott R, et al. Identification of tumor-reactive T cells targeting melanoma Dark Antigens™ validates this novel class of targets for development of immunotherapies. Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting. 2022;343.

  5. Jupp R, et al. Discovery of immunogenic ERV-derived antigens as targets for melanoma immunotherapy. Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting. 2019;P680.

Ethics Approval All work involving the use of human tissue was approved by the NHS Health Research Authority Northwest Haydock Research Ethics Committee (reference number 19/NW/0216). This study was conducted using TILs from patients enrolled in a clinical studies conducted at CCIT-DK. All patients signed a written consent form according to the Declaration of Helsinki. The studies were approved by the local ethics committee for the capital region of Denmark (Region H).

http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.